Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02563938 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001
A Phase 1 study, sponsored by Allakos.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02563938 is a Phase 1 study that has completed, run by Allakos. The registered enrollment target is 34 participants.
The verdict
NCT02563938, a Phase 1 study, has completed, sponsored by Allakos.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This first-in-human study will evaluate the safety and tolerability of single doses of AK001 across a range of potentially active doses. Early signals of pharmacodynamic activity will also be evaluated.
Interventions
- DRUG Placebo
- DRUG AK001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02563938
The ClinicalTrials.gov registry entry for NCT02563938 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allakos, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02563938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02563938 about?
NCT02563938 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001". This first-in-human study will evaluate the safety and tolerability of single doses of AK001 across a range of potentially active doses. Early signals of pharmacodynamic activity will also be evaluated.
What is the current status of trial NCT02563938?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2015-09. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02563938?
The interventions under investigation include: Placebo (DRUG), AK001 (DRUG).
Who is sponsoring clinical trial NCT02563938?
This trial is sponsored by Allakos, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.